News & Media

Otsuka Announces Positive Phase III Data on Tolvaptan, in Development in U.S. for ADPKD Trial achieved primary and secondary endpoints in an additional Phase III clinical trial that examined the efficacy and safety of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD)Aim is for data to support a full review by the FDA of a New Drug Application (NDA) for tolvaptan in ADPKDTrial

Centanafadine, an investigational compound for the treatment of ADHD, demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both studiesIn the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients An estimated 5 percent (11 million) adults in the U.S. are diagnosed

New Multi-year Public Health Campaign and Documentary Focus on Mental Health Issues PRINCETON, N.J. – May 21, 2020 – Otsuka America Pharmaceutical, Inc., announces that the company is the lead, founding sponsor of the WELL BEINGS Youth Mental Health Project, a multi-year, public health campaign launched by WETA, the flagship public broadcasting station in the nation’s capital.  The

Akebia Therapeutics announced that its vadadustat achieved the primary efficacy and cardiovascular safety endpoints in the studyTop-line data advance plans for vadadustat's New Drug Application and other global regulatory submissionsMay, 5, 2020 - Tokyo, Japan - Otsuka Pharmaceutical Co., Ltd. (president and representative director Makoto Inoue; headquarters in Tokyo; hereafter Otsuka) announces